BALTIMORE, Md., Feb. 17, 2010 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated coverage of Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics.
Rexahn has three drugs currently in Phase II clinical trials and each of these treatments has huge market potential. Rexahn's unique technology has already received validation via a commercialization agreement with, and equity investment by Teva Pharmaceutical, a top 20 global pharmaceutical firm.
In the Goldman Select Research report on the Company, analyst Rob Goldman gives a thorough explanation of Rexahn's unique therapeutic platform and potential competitive advantages. Goldman also presents his thesis that the current value of the Rexahn clinical and pre-clinical portfolio is not being properly reflected in the Company's market capitalization.
According to Goldman Small Cap Research analyst Rob Goldman, "The Company addresses unmet needs in large markets with a clever, proprietary mechanistic actions that should demonstrate greater efficacy and fewer side effects in current and present clinical trials. In our view, the Street has completely overlooked the fact that this company has blockbuster-type products with multiple indications per compound, already in Phase II trials. Yet, the present valuation is akin to a biotech one-trick pony. This presents a rare opportunity for investors to invest in a clinical drug firm with a broad and deep portfolio, at the current valuation of one-product firm."
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces stock market research reports. The Firm produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm's internally generated stock ideas while the Opportunity product reflects sponsored research reports. While performance is tracked separately, the same coverage criteria is utilized in determining coverage of all stocks in both research formats.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap research nor its parent is a registered investment adviser or broker-dealer. To download our research or for more information, visit www.goldmanresearch.com.
About Rexahn Pharmaceuticals: Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN) is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS (Central Nervous System) disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin™, Serdaxin®, and Zoraxel™ -- all potential best in class therapeutics -- and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms.www.rexahn.com